Evaluation of a Novel MET-Targeting Camelid-Derived Antibody in Head and Neck Cancer.
Minne RL, Luo NY, Mork CM, Wopat MR, Esbona K, Javeri S, Nickel KP, Hernandez R, LeBeau AM, Kimple RJ, Baschnagel AM.
Minne RL, et al. Among authors: hernandez r.
Mol Pharm. 2024 Nov 8. doi: 10.1021/acs.molpharmaceut.4c00938. Online ahead of print.
Mol Pharm. 2024.
PMID: 39513517